Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
UNICANCER
ClinicalTrials.gov Identifier:
NCT00967031
First received: August 26, 2009
Last updated: January 17, 2013
Last verified: January 2013

August 26, 2009
January 17, 2013
April 2009
February 2012   (final data collection date for primary outcome measure)
Objective response rate [ Time Frame: february 2012 ] [ Designated as safety issue: No ]
Objective response rate [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00967031 on ClinicalTrials.gov Archive Site
  • Toxicity as assessed by NCI CTC v3.0 [ Time Frame: february 2012 ] [ Designated as safety issue: Yes ]
  • Time to radiotherapy [ Time Frame: february 2012 ] [ Designated as safety issue: No ]
  • Time to disease progression [ Time Frame: february 2012 ] [ Designated as safety issue: No ]
  • Overall response rate [ Time Frame: february 2012 ] [ Designated as safety issue: No ]
  • Clinical benefit (complete response, partial response, and stable disease for at least 6 months) [ Time Frame: february 2012 ] [ Designated as safety issue: No ]
  • Evaluation of serum proteomics and metabonomics markers as predictors of response [ Time Frame: may 2012 ] [ Designated as safety issue: No ]
  • Evaluation of the predictive value of circulating tumor cells on response [ Time Frame: february 2012 ] [ Designated as safety issue: No ]
  • Toxicity as assessed by NCI CTC v3.0 [ Designated as safety issue: Yes ]
  • Time to radiotherapy [ Designated as safety issue: No ]
  • Time to disease progression [ Designated as safety issue: No ]
  • Overall response rate [ Designated as safety issue: No ]
  • Clinical benefit (complete response, partial response, and stable disease for at least 6 months) [ Designated as safety issue: No ]
  • Evaluation of serum proteomic and metabonomic markers as predictors of response [ Designated as safety issue: No ]
  • Evaluation of the predictive value of circulating tumor cells on response [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases
A Multicenter Phase II Clinical Trial Assessing the Efficacy of the Combination of Lapatinib and Capecitabine in Patients With Non Pretreated Brain Metastasis From HER2 Positive Breast Cancer

RATIONALE: Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib ditosylate together with capecitabine may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving lapatinib ditosylate together with capecitabine works in treating patients with stage IV breast cancer and brain metastases.

OBJECTIVES:

Primary

  • To assess the objective response rate by volumetric analysis of brain metastasis as assessed by MRI in patients with HER2-positive stage IV breast cancer treated with lapatinib ditosylate and capecitabine.

Secondary

  • To document any toxicity evaluated by NCI CTC v3.0.
  • To assess the time to radiotherapy.
  • To document the time to disease progression in the central nervous system (CNS) of these patients.
  • To evaluate the overall response rate for extra-CNS disease.
  • To assess the clinical benefit (complete response, partial response, and stable disease for ≥ 6 months) for both CNS and extra-CNS disease in these patients.

Tertiary

  • To evaluate serum proteomics and metabonomics markers as predictors of response.
  • To evaluate the predictive value of circulating tumor cells (CTC) on response.

OUTLINE: This is a multicenter study.

Patients receive oral lapatinib ditosylate once daily. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Breast Cancer
  • Metastatic Cancer
  • Drug: capecitabine
  • Drug: lapatinib ditosylate
  • Other: circulating tumor cell analysis
  • Other: laboratory biomarker analysis
Experimental: Lapatinib + capecitabine
lapatinib 1250mg/day + capecitabine 2000mg/m2/day
Interventions:
  • Drug: capecitabine
  • Drug: lapatinib ditosylate
  • Other: circulating tumor cell analysis
  • Other: laboratory biomarker analysis
Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Gonçalves A, Leheurteur M, Domont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013 Jan;14(1):64-71. doi: 10.1016/S1470-2045(12)70432-1. Epub 2012 Nov 2.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
45
Not Provided
February 2012   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed invasive breast cancer

    • Stage IV disease
  • At least 1 measurable CNS lesion ≥ 10 mm on T1-weighted gadolinium-enhanced MRI

    • No single brain metastasis that could be treated by surgery
  • HER-2 positive primary tumor as defined as IHC3+ or IHC2+ and FISH-positive
  • Hormone receptor status: not specified

PATIENT CHARACTERISTICS:

  • Menopausal status not specified
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Life expectancy ≥ 3 months
  • Absolute Neutrophil Count (ANC) ≥ 1,000/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 10g/dL
  • Creatinine ≥ 1.5 times upper limit of normal (ULN)
  • Albumin ≥ 2.5 g/dL
  • Serum bilirubin ≤ 1.5 times ULN (unless due to Gilbert's syndrome)
  • ASAT and ALAT ≤ 3 times ULN (≤ 5 times ULN with documented liver metastasis)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception 2 weeks before, during, and for 28 days after completion of study treatment (female) or for 1 week after completion of treatment (male)
  • Able to swallow and retain oral medication
  • Affiliated to a Social Security System
  • No known contraindication to MRI
  • No prior or active malignancy, unless disease free for ≥ 10 years
  • No other concurrent severe and/or uncontrolled medical disease which could compromise study participation, including any of the following:

    • Infection
    • Cardiac disease (e.g., uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within the past year, Left Ventricular EJection Fraction (LVEF) > grade 2)
    • Current active hepatic or biliary disease (except for Gilbert syndrome, asymptomatic gallstones, liver metastasis or stable chronic liver disease per investigator assessment)
    • Renal disease
    • Active gastrointestinal (GI) tract ulceration, malabsorption syndrome, active uncontrolled ulcerative colitis, or disease significantly affecting GI function
    • Severely impaired lung function (e.g., spirometry and diffusion capacity of lung for carbon monoxide (DLCO) ≤ 50% of normal, and O_2 saturation ≤ 88% at rest on room air)
  • No known dihydropyrimidine dehydrogenase deficiency
  • No significantly altered mental status prohibiting the understanding of the study, or with psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Not deprived of liberty or placed under the authority of a tutor

PRIOR CONCURRENT THERAPY:

  • At least 2 weeks since prior breast cancer treatment (e.g., trastuzumab, chemotherapy, immunotherapy or biological response modifiers, endocrine therapy, or radiotherapy)
  • More than 30 days since prior investigational drugs
  • More than 14 days since prior and no concurrent strong inhibitors or inducers of the cytochrome P450 isoenzyme 3A4 (CYP3A4) (i.e., clarithromycin, ketoconazole, itraconazole, voriconazole, ritonavir)
  • No prior whole brain radiotherapy (WBRT) or brain stereotactic radiotherapy
  • No prior treatment with capecitabine and/or lapatinib ditosylate
  • No prior resection of the stomach or small bowel
  • No concurrent systemic treatment or radiation therapy for breast cancer (except corticosteroid, bisphosphonates, or mannitol)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00967031
CDR0000642631, EU-20940, GEP 02-0801, 2008-001084-10
No
UNICANCER
UNICANCER
Not Provided
Principal Investigator: Thomas Bachelot, MD Centre Leon Berard
UNICANCER
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP